Download PDF
Thromb Haemost 2017; 117(10): 1952-1961
DOI: 10.1160/TH17-03-0193
Trial Protocol Design Paper
Schattauer GmbH

Apixaban and dalteparin in active malignancy associated venous thromboembolism

The ADAM VTE Trial
Robert McBane II
1   Mayo Clinic, Rochester, Minnesota, USA
,
Charles L. Loprinzi
1   Mayo Clinic, Rochester, Minnesota, USA
,
Aneel Ashrani
1   Mayo Clinic, Rochester, Minnesota, USA
,
Juliana Perez Botero
1   Mayo Clinic, Rochester, Minnesota, USA
,
Roberto A. Leon Ferre
1   Mayo Clinic, Rochester, Minnesota, USA
,
Stanislav Henkin
1   Mayo Clinic, Rochester, Minnesota, USA
,
Charles J. Lenz
1   Mayo Clinic, Rochester, Minnesota, USA
,
Jennifer G. Le-Rademacher
1   Mayo Clinic, Rochester, Minnesota, USA
,
Waldemar E. Wysokinski
1   Mayo Clinic, Rochester, Minnesota, USA
› Author Affiliations
Further Information

Publication History

Received: 18 March 2017

Accepted after major revision: 24 June 2017

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Currently, low molecular weight heparin (LMWH) is the guideline endorsed treatment of patients with cancer associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, there are limited data supporting its use in cancer patients. The rationale and design of this investigator initiated Phase IV, multicenter, randomized, open label, superiority trial assessing the safety of apixaban versus dalteparin for cancer associated VTE is provided (ADAM-VTE; NCT02585713). The main aim of the ADAM-VTE trial is to test the hypothesis that apixaban is associated with a significantly lower rate of major bleeding compared to dalteparin in the treatment of cancer patients with acute VTE. The primary safety outcome is rate of major bleeding. Secondary efficacy objective is to assess the rates of recurrent VTE or arterial thromboembolism. Cancer patients with acute VTE (n=300) are randomized to receive apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily thereafter) or dalteparin (200 IU/Kg daily for 30 days followed by 150 IU/kg daily thereafter) for 6 months. Stratification factors used for randomization include cancer stage and cancer specific risk of venous thromboembolism using the Khorana score. Participating centers are chosen from the Academic and Community Cancer Research United (ACCRU) consortium comprised of 90 oncology practices in the United States and Canada. Based on the hypothesis to be tested, we anticipate that these trial results will provide evidence supporting apixaban as an effective treatment of cancer associated VTE at lower rates of major bleeding compared to LMWH.

Key words

Cancer - venous thromboembolism - apixaban - dalteparin
 

  • References

  • 1 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437-445.
    PubMedGoogle Scholar
  • 2 Nordstrom M, Lindblad B, Anderson H. et al. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-894.
    CrossrefPubMedGoogle Scholar
  • 3 Prandoni P, Lensing AW, Büller HR. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133.
    CrossrefPubMedGoogle Scholar
  • 4 Monreal M, Falgá C, Valdés M. et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 04: 1950-1956.
    CrossrefPubMedGoogle Scholar
  • 5 Heit JA, Silverstein MD, Mohr DN. et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
    CrossrefPubMedGoogle Scholar
  • 6 Chee CE, Ashrani AA, Marks RS. et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014; 123: 3972-3978.
    CrossrefPubMedGoogle Scholar
  • 7 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 05: 632-634.
    CrossrefPubMedGoogle Scholar
  • 8 Sorensen HT, Mellemkjaer L, Olsen JH. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
    CrossrefPubMedGoogle Scholar
  • 9 Chew HK, Wun T, Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
    CrossrefPubMedGoogle Scholar
  • 10 McBane RD, Wysokinski WE, Daniels PR. et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2010; 30: 442-448.
    CrossrefPubMedGoogle Scholar
  • 11 Ashrani AA, Heit JA. Risk factors for thrombosis in cancer patients. Cancer Treat Res 2009; 148: 95-114.
    PubMedGoogle Scholar
  • 12 Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010; 102 (Suppl. 01) S2-S9.
    CrossrefPubMedGoogle Scholar
  • 13 Ashrani AA, Rajkumar SV. Chemotherapy-associated thrombosis. Cancer Treat Res 2009; 148: 181-206.
    PubMedGoogle Scholar
  • 14 Prandoni P, Trujillo-Santos J, Surico T. et al. Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry. Haematologica 2008; 93: 1432-1434.
    CrossrefPubMedGoogle Scholar
  • 15 Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A. et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 (02) S58-S61.
    CrossrefPubMedGoogle Scholar
  • 16 Tafur AJ, Wysokinski WE, McBane RD. et al. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol 2012; 23: 1998-2005.
    CrossrefPubMedGoogle Scholar
  • 17 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-352.
    CrossrefPubMedGoogle Scholar
  • 18 Lee AYY, Levine MN, Baker RI. et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2003; 349: 146-153.
    CrossrefPubMedGoogle Scholar
  • 19 Lee AY, Rickles FR, Julian JA. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
    CrossrefPubMedGoogle Scholar
  • 20 Meyer G, Marjanovic Z, Valcke J. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
    CrossrefPubMedGoogle Scholar
  • 21 Deitcher SR, Kessler CM, Merli G. et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389-396.
    CrossrefPubMedGoogle Scholar
  • 22 Hull RD, Pineo GF, Brant RF. et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
    CrossrefPubMedGoogle Scholar
  • 23 Lee AY, Kamphuisen PW, Meyer G. et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. J Am Med Assoc 2015; 314: 677-686.
    CrossrefPubMedGoogle Scholar
  • 24 Song Y, Chang M, Suzuki A. et al. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Clin Ther 2016; 38: 1674-1685.
    CrossrefPubMedGoogle Scholar
  • 25 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
    CrossrefPubMedGoogle Scholar
  • 26 Schulman S, Angerås U, Bergqvist D. et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 08: 202-204.
    CrossrefPubMedGoogle Scholar
  • 27 Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 30 (368) 2113-2124.
    PubMedGoogle Scholar
  • 28 Agnelli G, Buller HR, Cohen A. et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med 2013; 369: 799-808.
    CrossrefPubMedGoogle Scholar
  • 29 Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
    CrossrefPubMedGoogle Scholar
  • 30 Einstein PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
    CrossrefPubMedGoogle Scholar
  • 31 Vedovati MC, Germini F, Agnelli G. et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147: 475-483.
    CrossrefPubMedGoogle Scholar
  • 32 Hokusai-VTE Investigators. Büller HR, Décousus H. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
    CrossrefPubMedGoogle Scholar
  • 33 Raskob GE, van Es N, Segers A. et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 2016; 03: e379-387.
    PubMedGoogle Scholar
  • 34 Frost C, Song Y, Barrett YC. et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 06: 179-187.
    PubMedGoogle Scholar
  • 35 https://clinicaltrials.gov/ct2/show/NCT02581176
    PubMed
  • 36 https://clinicaltrials.gov/ct2/show/record/NCT02744092
    PubMed
  • 37 https://clinicaltrials.gov/ct2/show/NCT02583191
    PubMed
  • 38 https://clinicaltrials.gov/ct2/show/NCT02742623
    PubMed
  • 39 van Es N, Di Nisio M, Bleker SM. et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015; 114: 1268-1276.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 https://clinicaltrials.gov/ct2/show/NCT02555878
    PubMed
  • 41 http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/trials/cancer/select-d/select-d_protocol_v2.0_09-apr-2013.pdf
    PubMed